Santen Pharmaceutical Co., Ltd. announced consolidated and non-consolidated earnings results for the year ended March 31, 2019. For the year, on consolidated basis, the company reported revenue of JPY 234,026 million as compared to JPY 224,942 million for the same period last year. Operating profit was JPY 45,098 million as compared to JPY 38,691 million for the same period last year. Net profit for the year was JPY 31,943 million as compared to JPY 35,261 million for the same period last year. Diluted earnings per share were JPY 78.43 as compared to JPY 86.42 for the same period last year. Basic earnings per share were JPY 78.67 as compared to JPY 86.73 for the same period last year.

For the year, on non-consolidated basis, the company reported net sales of JPY 176,208 million compared with JPY 171,872 million for the same period a year ago. Operating income was JPY 32,849 million compared with JPY 31,298 million for the same period a year ago. Net income was JPY 28,014 million compared with JPY 25,435 million for the same period a year ago. Diluted net income per share was JPY 68.76 compared with JPY 62.36 for the same period a year ago. Net income per share was JPY 68.96 compared with JPY 62.58 for the same period a year ago.

The company provided consolidated earnings guidance for the full year ending March 31, 2020. For the year, the company expects to report revenues of JPY 248,000 million, operating profit of JPY 34,500 million, net profit for the year of JPY 23,200 million or JPY 58.98 per basic share.